Steven Perrin
Equibles does not estimate personal net worth.
Get an email with a short summary when Eledon Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ELDN alertsAbout Steven Perrin
Steven Perrin is recorded as Board Member at Eledon Pharmaceuticals, Inc. (ELDN). The newest filing on record that lists Steven Perrin as Board Member at Eledon Pharmaceuticals, Inc. (ELDN) is dated April 30, 2026. Eledon Pharmaceuticals, Inc. reported in an 8-K filed July 10, 2024 that Steven Perrin was appointed Class I Director, effective July 10, 2024. The proxy statement of Eledon Pharmaceuticals, Inc. reports total compensation of $1,696,284 for Steven Perrin in fiscal 2025, including a base salary of $484,919. Disclosed compensation is on record for 6 fiscal years. Eledon Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Eledon Pharmaceuticals, Inc. includes David-Alexandre "DA" C. Gros, M.D. (CEO and Board Member), David-Alexandre C. Gros (CEO and Board Member), David-Alexandre C. Gros, M.D. (CEO and Board Member) and 7 others.
“The stockholders of the Company elected Steven Perrin, Ph.D. and June Lee, M.D. as Class I Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 30, 2026
-
Eledon Pharmaceuticals, Inc. (ELDN)
Proxy statement
CurrentStart not stated–present
Last confirmed April 30, 2026
Company network
Leadership on record at Eledon Pharmaceuticals, Inc.
- David-Alexandre "DA" C. Gros, M.D. CEO, Board Member
- David-Alexandre C. Gros CEO, Board Member
- David-Alexandre C. Gros, M.D. CEO, Board Member
- David-Alexandre Gros CEO, Board Member
- Jon Kuwahara CEO
- Paul Little CFO, Chief Accounting Officer
- Bryan Smith General Counsel
- Allan D. Kirk Board Member
- Allan Douglas Kirk, MD, PhD, FACS Board Member
- James Robinson Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Eledon Pharmaceuticals, Inc. (ELDN) | President and Chief Scientific Officer | $484,919 | $1,696,284 |
| 2024 | Eledon Pharmaceuticals, Inc. (ELDN) | President and Chief Scientific Officer | $455,258 | $4,571,222 |
| 2023 | Eledon Pharmaceuticals, Inc. (ELDN) | President and Chief Scientific Officer | $437,439 | $1,540,583 |
| 2022 | Eledon Pharmaceuticals, Inc. (ELDN) | President and Chief Scientific Officer | $417,052 | $1,049,577 |
| 2021 | Eledon Pharmaceuticals, Inc. (ELDN) | President and Chief Scientific Officer | $402,923 | $566,813 |
| 2020 | Eledon Pharmaceuticals, Inc. (ELDN) | Ph.D.^(^^3)^ President and Chief Scientific Officer | $122,308 | $3,113,055 |